NCT06658899View on ClinicalTrials.gov

A Phase 2 Study of CRD-4730 in CPVT

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
DRUG

CRD-4730

Oral CRD-4730 in tablet form

DRUG

Placebo

Placebo to match CRD-4730 in tablet form

Sponsors
All Listed Sponsors
lead

Cardurion Pharmaceuticals, Inc.

INDUSTRY